

What is claimed is:

1. A method for treating HIV encephalopathy which comprises administering to an HIV-infected human suffering from HIV encephalopathy a therapeutically effective amount of pramipexole or a pharmacologically acceptable acid addition salt thereof.
2. The method of claim 1 wherein the (+) enantiomer of pramipexole is employed.
3. The method of claim 1 wherein the (-) enantiomer of pramipexole is employed.
4. A method for treating an HIV-associated motor disorder which comprises administering to an HIV-infected human suffering from an HIV-associated motor disorder a therapeutically effective amount of pramipexole or a pharmacologically acceptable acid addition salt thereof.
5. The method of claim 1 wherein the (+) enantiomer of pramipexole is employed.
6. The method of claim 1 wherein the (-) enantiomer of pramipexole is employed.
7. A method for treating an HIV-associated cognitive impairment which comprises administering to an HIV-infected human suffering from an HIV-associated cognitive impairment a therapeutically effective amount of pramipexole or a pharmacologically acceptable acid addition salt thereof.
8. The method of claim 1 wherein the (+) enantiomer of pramipexole is employed.
9. The method of claim 1 wherein the (-) enantiomer of pramipexole is employed.

10. A method for treating an HIV-associated motor disorder which comprises administering to an HIV-infected human suffering from an HIV-associated behavioural disorder a therapeutically effective amount of pramipexole or a pharmacologically acceptable acid addition salt thereof.
- 5
11. The method of claim 1 wherein the (+) enantiomer of pramipexole is employed.
12. The method of claim 1 wherein the (-) enantiomer of pramipexole is employed.
- 10 13. A method for treating HIV infection which comprises administering to an HIV-infected person pramipexole and one or more additional active substances selected from the group consisting of nucleoside and non-nucleoside inhibitors of reverse transcriptase, HIV protease inhibitors and other HIV replication inhibitors, antiviral active substances within the scope of an HAART (highly active antiretroviral
- 15 therapy), AIDS vaccines and inhibitors of virus adhesion and virus uptake in mammalian cells.